Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreve (casirivimab and imdevimab) in patients hospitalized with COVID-19. The trial met its primary endpoint, showing significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response and who required low-flow or no supplemental oxygen.    The study also reported clinical results supportive of the larger UK RECOVERY trial in hospitalized patients showing t...